Core Viewpoint - EUDA Health Holdings Limited has entered into a convertible loan agreement with Shenzhen Inno Immune Co., Ltd to support the upgrade of Shenzhen Inno's cGMP facility, enhancing EUDA's regenerative medicine capabilities in China [1][3]. Investment Details - EUDA plans to invest up to RMB 6 million in two tranches: an initial tranche of RMB 1 million and a second tranche of RMB 5 million, contingent on due diligence and regulatory approvals [2]. - The investment is structured as a convertible loan note with a 6% annual interest rate, payable semi-annually, and may be redeemed with accrued interest if not converted [4]. Facility and Technology Development - Shenzhen Inno will utilize the capital to upgrade its facility in Shenzhen, creating a state-of-the-art production and innovation center for stem cell treatments, which will serve as a core technology hub for EUDA's strategy in China [3]. - The facility will support international collaborations and provide a replicable platform for expansion into additional cities and markets [3]. Company Background - EUDA Health Holdings Limited is a leading non-invasive healthcare provider in Asia, focusing on Singapore, Malaysia, and China, with a mission to address the healthcare needs of over 1.8 billion people in the region [8]. - The company aims to lead the transformation of regional healthcare from reactive treatment to proactive, longevity-focused care, particularly in the fast-growing longevity sector [8]. Strategic Vision - The CEO of EUDA emphasized that the agreement reflects a disciplined approach to building long-term stem cell therapy platforms, aiming for deeper ownership and integration over time [7].